+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunoglobulin decrease accompanying adverse reactions with bucillamine

Immunoglobulin decrease accompanying adverse reactions with bucillamine

Ryumachi 33(4): 316-324

Forty-two RA patients treated with Bucillamine (B) were divided into two groups with (n = 26) and without (n = 16) adverse reactions, and IgG, M, A and total protein concentration x globulin ratio (Ig) before and after B were compared. IgG did not differ before B administration, but was significantly lower in the adverse reactions group after B, and in each group it was significantly lower after B treatment with a much greater decrease demonstrated in the adverse reactions group. IgA before B did not differ either between the two groups or between before and after B administration in the non-adverse reaction group, but was significantly lower only after B in the adverse reaction group. IgM did not differ either before or after B treatment between the two groups, and was significantly lower following B administration in both groups. Ig showed results similar to IgA. In the adverse reaction group, IgG, A, M and Ig recovered following suspension of administration. It is concluded that the adverse reaction brought on by B administration might occur with the decrease in immunoglobulin.

(PDF emailed within 1 workday: $29.90)

Accession: 046333229

Download citation: RISBibTeXText

PMID: 8235913

Related references

Immunoglobulin and lymphocyte decrease concurrent with adverse reactions induced by methotrexate for RA. Annals of the Rheumatic Diseases 59(6): 495-496, 2000

Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 121(3): E626-E630, 2008

Adverse reactions of intravenous immunoglobulin. Saudi Medical Journal 21(10): 953-956, 2001

Intravenous immunoglobulin: adverse reactions and management. Journal of Allergy and Clinical Immunology 122(6): 1238-1239, 2009

Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis. Documenta Ophthalmologica. Advances in Ophthalmology 75(3-4): 215-224, 1990

Immunoglobulin and LST in RA patients treated with bucillamine. Ryumachi 35(1): 38-45, 1995

Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin. Drug Safety 2(1): 9-18, 2007

Adverse reactions and pathogen safety of intravenous immunoglobulin. Current Drug Safety 2(1): 9-18, 2008

Non immunoglobulin e mediated and delayed adverse reactions to food or additives. Breneman, J C (Ed ) Immunology Series, Vol 29 Handbook Of Food Allergies Xiii+297p Marcel Dekker, Inc : New York, N Y , Usa; Basel, Switzerland Illus 125-162, 1987

The use of in line infusion filters relieves adverse reactions to intravenous immunoglobulin iv ig. Journal of Allergy & Clinical Immunology 79(1): 198, 1987

Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. Journal of Clinical Immunology 15(2): 116-119, 1995

Different patterns of cytokines, ECP and immunoglobulin profiles at two adverse drug reactions in a patient. Pediatrics International 47(6): 616-621, 2005

Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience. European Annals of Allergy and Clinical Immunology 49(1): 11-14, 2017

Intravenous immunoglobulin in the Guillain-Barré syndrome. May cause severe adverse skin reactions. Bmj 313(7069): 1399-1400, 1996

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials. Journal of Clinical Immunology 37(6): 517-518, 2017